|
|
|
Hepatitis Clinical Trials, Diagnosis, and Treatment |
|
Thank you for your interest in clinical trials for
Hepatitis.
Please click "Search" to find Hepatitis clinical trials and medical research
studies or read below for information on Hepatitis diagnosis and treatment.
If you receive too many study listings you may enter your zip code to find the
locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 5 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-01107
Conditions: Hepatitis C Location: Springfield, MA
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-10021
Conditions: Hepatitis C Location: New York, NY
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-10065
Conditions: Hepatitis C Location: New York, NY
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-32803
Conditions: Hepatitis C Location: Orlando, FL
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-37205
Conditions: Hepatitis C Location: Nashville, TN
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-74135
Conditions: Hepatitis C Location: Tulsa, OK
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-78215
Conditions: Hepatitis C Location: San Antonio, TX
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-92037
Conditions: Hepatitis C Location: La Jolla, CA
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-94115
Conditions: Hepatitis C Location: San Francisco, CA
- A Network & Dyad HIV Prevention Intervention for IDU's - 1 - NCT00218335-21231
Conditions: HIV - Hepatitis Location: Baltimore, MD
- A Phase II Study to Determine the Safety and Efficacy of Interferon-Gamma in Patients With Chronic Hepatitis B - NCT00753467-91105
Conditions: Hepatitis B Location: Pasadena, CA
- A Pilot Study of Siliphos in Adults With Non-Alcoholic Steatohepatitis (NASH) - NCT00443079-92103
Conditions: Fatty Liver Location: San Diego, CA
- A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C - NCT00814606-60637
Conditions: Hepatitis C - Hepatitis C Virus Location: Chicago, IL
- A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) - NCT00799578-92103
Conditions: Fatty Liver Location: San Diego, CA
- A Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104
Conditions: Chronic Hepatitis C Location: OKlahoma City, OK
- A Rollover Protocol to Provide Subjects Completing the GS-US-203-0107 Study Continued Access to the Fixed Dose Combination Product Emtricitabine/Tenofovir Disoproxil Fumarate - NCT00936715-
Conditions: Chronic Hepatitis B Location: New York, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-02114
Conditions: Hepatitis C, Chronic Location: BOSTON, MA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-07061
Conditions: Hepatitis C, Chronic Location: HACKENSACK, NJ
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-08234
Conditions: Hepatitis C, Chronic Location: EGG HARBOUR TOWNSHIP, NJ
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10016
Conditions: Hepatitis C, Chronic Location: NEW YORK, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10021
Conditions: Hepatitis C, Chronic Location: NEW YORK, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-13210
Conditions: Hepatitis C, Chronic Location: SYRACUSE, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22031
Conditions: Hepatitis C, Chronic Location: FAIRFAX, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22908
Conditions: Hepatitis C, Chronic Location: CHARLOTTESVILLE, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-23249
Conditions: Hepatitis C, Chronic Location: RICHMOND, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27103
Conditions: Hepatitis C, Chronic Location: WINSTON-SALEM, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27599
Conditions: Hepatitis C, Chronic Location: CHAPEL HILL, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-28801
Conditions: Hepatitis C, Chronic Location: ASHEVILLE, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30060
Conditions: Hepatitis C, Chronic Location: MARIETTA, GA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30308
Conditions: Hepatitis C, Chronic Location: ATLANTA, GA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32256
Conditions: Hepatitis C, Chronic Location: JACKSONVILLE, FL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32803
Conditions: Hepatitis C, Chronic Location: ORLANDO, FL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-35294
Conditions: Hepatitis C, Chronic Location: BIRMINGHAM, AL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-37660
Conditions: Hepatitis C, Chronic Location: KINGSPORT, TN
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-38801
Conditions: Hepatitis C, Chronic Location: TUPELO, MS
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63104
Conditions: Hepatitis C, Chronic Location: ST LOUIS, MO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63110
Conditions: Hepatitis C, Chronic Location: ST LOUIS, MO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70520
Conditions: Hepatitis C, Chronic Location: OPELOUSAS, LA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70890
Conditions: Hepatitis C, Chronic Location: BATON ROUGE, LA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-73112
Conditions: Hepatitis C, Chronic Location: OKLAHOMA CITY, OK
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-78234
Conditions: Hepatitis C, Chronic Location: FORT SAM HOUSTON, TX
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-80045
Conditions: Hepatitis C, Chronic Location: AURORA, CO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-84132
Conditions: Hepatitis C, Chronic Location: SALT LAKE CITY, UT
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-87131
Conditions: Hepatitis C, Chronic Location: ALBUQUERQUE, NM
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90048
Conditions: Hepatitis C, Chronic Location: LOS ANGELES, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90057
Conditions: Hepatitis C, Chronic Location: LOS ANGELES, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90505
Conditions: Hepatitis C, Chronic Location: TORRANCE, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90822
Conditions: Hepatitis C, Chronic Location: LONG BEACH, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92037
Conditions: Hepatitis C, Chronic Location: LA JOLLA, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92103
Conditions: Hepatitis C, Chronic Location: SAN DIEGO, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-93534
Conditions: Hepatitis C, Chronic Location: LANCASTER, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-94115
Conditions: Hepatitis C, Chronic Location: SAN FRANCISCO, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95816
Conditions: Hepatitis C, Chronic Location: SACRAMENTO, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95817
Conditions: Hepatitis C, Chronic Location: SACRAMENTO, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-96813
Conditions: Hepatitis C, Chronic Location: HONOLULU, HI
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-97239
Conditions: Hepatitis C, Chronic Location: PORTLAND, OR
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02115
Conditions: Hepatitis B, Chronic Location: Boston, MA
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02903
Conditions: Hepatitis B, Chronic Location: Providence, RI
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-06106
Conditions: Hepatitis B, Chronic Location: Hartford, CT
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-10029
Conditions: Hepatitis B, Chronic Location: New York, NY
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-19104
Conditions: Hepatitis B, Chronic Location: Philadelphia, PA
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-21287
Conditions: Hepatitis B, Chronic Location: Baltimore, MD
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-32601
Conditions: Hepatitis B, Chronic Location: Gainesville, FL
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-75390
Conditions: Hepatitis B, Chronic Location: Dallas, TX
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-94143
Conditions: Hepatitis B, Chronic Location: San Francisco, CA
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Baltimore, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Bethesda, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Baltimore, MD
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-02905
Conditions: Hepatitis C, Chronic Location: PROVIDENCE, RI
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-10021
Conditions: Hepatitis C, Chronic Location: NEW YORK, NY
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-11030
Conditions: Hepatitis C, Chronic Location: MANHASSET, NY
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-21205
Conditions: Hepatitis C, Chronic Location: BALTIMORE, MD
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-23249
Conditions: Hepatitis C, Chronic Location: RICHMOND, VA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-27599
Conditions: Hepatitis C, Chronic Location: CHAPEL HILL, NC
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-37211
Conditions: Hepatitis C, Chronic Location: NASHVILLE, TN
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-78215
Conditions: Hepatitis C, Chronic Location: SAN ANTONIO, TX
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-84132
Conditions: Hepatitis C, Chronic Location: SALT LAKE CITY, UT
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-85054
Conditions: Hepatitis C, Chronic Location: PHOENIX, AZ
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-92103
Conditions: Hepatitis C, Chronic Location: SAN DIEGO, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-94115
Conditions: Hepatitis C, Chronic Location: SAN FRANCISCO, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-95817
Conditions: Hepatitis C, Chronic Location: SACRAMENTO, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-97239
Conditions: Hepatitis C, Chronic Location: PORTLAND, OR
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-02905
Conditions: Hepatitis C, Chronic Location: PROVIDENCE, RI
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-07102
Conditions: Hepatitis C, Chronic Location: NEWARK, NJ
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-10021
Conditions: Hepatitis C, Chronic Location: NEW YORK, NY
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-17033
Conditions: Hepatitis C, Chronic Location: HERSHEY, PA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-20037
Conditions: Hepatitis C, Chronic Location: WASHINGTON, DC
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-21093
Conditions: Hepatitis C, Chronic Location: LUTHERVILLE, MD
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-23249
Conditions: Hepatitis C, Chronic Location: RICHMOND, VA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-29204
Conditions: Hepatitis C, Chronic Location: COLUMBIA, SC
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-30060
Conditions: Hepatitis C, Chronic Location: MARIETTA, GA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-32610
Conditions: Hepatitis C, Chronic Location: GAINESVILLE, FL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-34243
Conditions: Hepatitis C, Chronic Location: SARASOTA, FL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-35294
Conditions: Hepatitis C, Chronic Location: BIRMINGHAM, AL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-37211
Conditions: Hepatitis C, Chronic Location: NASHVILLE, TN
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-60637
Conditions: Hepatitis C, Chronic Location: CHICAGO, IL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-64131
Conditions: Hepatitis C, Chronic Location: KANSAS CITY, MO
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-77030
Conditions: Hepatitis C, Chronic Location: HOUSTON, TX
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-78234
Conditions: Hepatitis C, Chronic Location: FORT SAM HOUSTON, TX
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-92037
Conditions: Hepatitis C, Chronic Location: LA JOLLA, CA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-92103
Conditions: Hepatitis C, Chronic Location: SAN DIEGO, CA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-94115
Conditions: Hepatitis C, Chronic Location: SAN FRANCISCO, CA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-95817
Conditions: Hepatitis C, Chronic Location: SACRAMENTO, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-10029
Conditions: Hepatitis C, Chronic Location: NEW YORK, NY
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-11030
Conditions: Hepatitis C, Chronic Location: MANHASSET, NY
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-17604
Conditions: Hepatitis C, Chronic Location: LANCASTER, PA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-27599
Conditions: Hepatitis C, Chronic Location: CHAPEL HILL, NC
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-28801
Conditions: Hepatitis C, Chronic Location: ASHEVILLE, NC
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-32256
Conditions: Hepatitis C, Chronic Location: JACKSONVILLE, FL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-32610
Conditions: Hepatitis C, Chronic Location: GAINESVILLE, FL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-32809
Conditions: Hepatitis C, Chronic Location: ORLANDO, FL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-48109
Conditions: Hepatitis C, Chronic Location: ANN ARBOR, MI
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-48202
Conditions: Hepatitis C, Chronic Location: DETROIT, MI
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-60148
Conditions: Hepatitis C, Chronic Location: LOMBARD, IL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-70112
Conditions: Hepatitis C, Chronic Location: NEW ORLEANS, LA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-78215
Conditions: Hepatitis C, Chronic Location: SAN ANTONIO, TX
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-80045
Conditions: Hepatitis C, Chronic Location: AURORA, CO
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-84132
Conditions: Hepatitis C, Chronic Location: SALT LAKE CITY, UT
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-85054
Conditions: Hepatitis C, Chronic Location: PHOENIX, AZ
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-90045
Conditions: Hepatitis C, Chronic Location: LOS ANGELES, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-90822
Conditions: Hepatitis C, Chronic Location: LONG BEACH, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-92123
Conditions: Hepatitis C, Chronic Location: SAN DIEGO, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-92154
Conditions: Hepatitis C, Chronic Location: SAN DIEGO, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-95817
Conditions: Hepatitis C, Chronic Location: SACRAMENTO, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-97504
Conditions: Hepatitis C, Chronic Location: MEDFORD, OR
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-98664
Conditions: Hepatitis C, Chronic Location: VANCOUVER, WA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-23249
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Richmond, VA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-32809
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Orlando, FL
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-33607
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Tampa, FL
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-34243
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Sarasota, FL
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-77030A
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Houston, TX
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-77030B
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Houston, TX
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-78215
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: San Antonio, TX
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-85054
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Phoenix, AZ
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-92105
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: San Diego, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-93721
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Fresno, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-94115
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: San Francisco, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-95817
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Sacramento, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-96817
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Honolulu, HI
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-10468
Conditions: Hepatitis C Location: Bronx, NY
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-92161
Conditions: Hepatitis C Location: San Diego, CA
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-94304
Conditions: Hepatitis C Location: Palo Alto, CA
- Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95661
Conditions: Hepatitis C Location: Roseville, CA
- Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95825
Conditions: Hepatitis C Location: Sacramento, CA
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-14642
Conditions: Hepatitis B, Chronic Location: Rochester, NY
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-45267
Conditions: Hepatitis B, Chronic Location: Cincinnati, OH
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-55905
Conditions: Hepatitis B, Chronic Location: Rochester, MN
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-60611
Conditions: Hepatitis B, Chronic Location: Chicago, IL
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-68198
Conditions: Hepatitis B, Chronic Location: Omaha, NE
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-70112
Conditions: Hepatitis B, Chronic Location: New Orleans, LA
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-75246
Conditions: Hepatitis B, Chronic Location: Dallas, TX
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-77030
Conditions: Hepatitis B, Chronic Location: Houston, TX
- Antiviral Effect and Safety of BI201335 +PegIFN/RBV in HCV-GT1 - NCT00774397-
Conditions: Hepatitis C, Chronic Location: Austin, TX
- Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-92103
Conditions: Chronic Hepatitis C Infection Location: San Diego, CA
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-55417
Conditions: Hepatitis C - Alcohol Use Disorders Location: Minneapolis, MN
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-90822
Conditions: Hepatitis C - Alcohol Use Disorders Location: Long Beach, CA
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-97201
Conditions: Hepatitis C - Alcohol Use Disorders Location: Portland, OR
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-07102
Conditions: Hepatitis C Virus - HIV Infections Location: Newark, NJ
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-21287
Conditions: Hepatitis C Virus - HIV Infections Location: Baltimore, MD
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-75204
Conditions: Hepatitis C Virus - HIV Infections Location: Dallas, TX
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-92663
Conditions: Hepatitis C Virus - HIV Infections Location: Newport Beach, CA
- Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects - NCT00136214-02215
Conditions: Hepatitis C Location: Boston, MA
- Characterization of Clonal B Cell Populations in HCV Infection - NCT00435201-10065
Conditions: Hepatitis C Location: New York, NY
- Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-96817
Conditions: Hepatitis C - Thrombocytopaenia Location: Honolulu, HI
- Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age - NCT00289913
Conditions: Hepatitis A Virus Location: Huntington, WV
- Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children - NCT00677183-53226
Conditions: Non-Alcoholic Steatohepatitis Location: Milwaukee, WI
- Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity - NCT00878592-15213
Conditions: Post Liver Transplantation Weight Gain - Post Liver Transplantation Obesity - Nonalcoholic Steatohepatitis Location: Pittsburgh, PA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-01107
Conditions: Hepatitis B Infection Location: Springfield, MA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-02115
Conditions: Hepatitis B Infection Location: Boston, MA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-02905
Conditions: Hepatitis B Infection Location: Providence, RI
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10003
Conditions: Hepatitis B Infection Location: New York, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10010
Conditions: Hepatitis B Infection Location: New York, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10701
Conditions: Hepatitis B Infection Location: Yonkers, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-19141
Conditions: Hepatitis B Infection Location: Philadelphia, PA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-20740
Conditions: Hepatitis B Infection Location: College Park, MD
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-33136
Conditions: Hepatitis B Infection Location: Miami, FL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-33144
Conditions: Hepatitis B Infection Location: Miami, FL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-36116
Conditions: Hepatitis B Infection Location: Montgomery, AL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-60612
Conditions: Hepatitis B Infection Location: Chicago, IL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-60637
Conditions: Hepatitis B Infection Location: Chicago, IL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-70121
Conditions: Hepatitis B Infection Location: New Orleans, LA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-78215
Conditions: Hepatitis B Infection Location: San Antonio, TX
- Effective Treatment of Hepatitis C in Substance Users - NCT00633243-06519
Conditions: Hepatitis C - Opiate Dependence Location: New Haven, CT
- Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C - NCT00876174-68198
Conditions: Chronic Hepatitis C Location: Omaha, NE
- Effects of HIV and Hepatitis C Virus on the Brain - NCT00494936-10029
Conditions: HIV Infections - Hepatitis C Location: New York, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-14642
Conditions: Acute On Chronic Hepatitis Location: Rochester, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-19104
Conditions: Acute On Chronic Hepatitis Location: Philadelphia, PA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-19140
Conditions: Acute On Chronic Hepatitis Location: Philadelphia, PA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-22908
Conditions: Acute On Chronic Hepatitis Location: Charlottesville, VA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-35294
Conditions: Acute On Chronic Hepatitis Location: Birmingham, AL
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-46202
Conditions: Acute On Chronic Hepatitis Location: Indianapolis, IN
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-60637
Conditions: Acute On Chronic Hepatitis Location: Chicago, IL
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-90048
Conditions: Acute On Chronic Hepatitis Location: Los Angeles, CA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-92037
Conditions: Acute On Chronic Hepatitis Location: La Jolla, CA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-94115
Conditions: Acute On Chronic Hepatitis Location: San Francisco, CA
- Efficacy and Safety Study of GS-9450 Treatment for 6 Months With in Patients With Chronic Hepatitis C Virus Infection - NCT00874796-
Conditions: HCV Infection Location: Madison, WI
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-75208
Conditions: Chronic Hepatitis C Virus Infection Location: Dallas, TX
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection - NCT01001754-78215
Conditions: Chronic Hepatitis C Virus Infection Location: San Antonio, TX
- Efficacy of Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant Chronic Hepatitis C (CHC) Genotype 1 (GT 1) Subjects - NCT00926016-78234
Conditions: Chronic Hepatitis C Location: San Antonio, TX
- Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks - NCT00862706-02111
Conditions: Compensated Chronic Hepatitis B Location: Boston, MA
- Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks - NCT00862706-11358
Conditions: Compensated Chronic Hepatitis B Location: Bayside, NY
- Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks - NCT00862706-60612
Conditions: Compensated Chronic Hepatitis B Location: Chicago, IL
- Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks - NCT00862706-77030A
Conditions: Compensated Chronic Hepatitis B Location: Houston, TX
- Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks - NCT00862706-77030B
Conditions: Compensated Chronic Hepatitis B Location: Houston, TX
- Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection - NCT00662545-94110
Conditions: HIV Infections - Hepatitis B Location: San Francisco, CA
- Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus - NCT00410202-06030
Conditions: Hepatitis B, Chronic Location: Farmington, CT
- Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection - NCT00004850-20892
Conditions: Hepatitis C Location: Bethesda, MD
- Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients - NCT00998426-20007
Conditions: Hepatitis B Location: Washington, DC
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-01805
Conditions: Hepatitis B - Liver Transplantation Location: Boston, MA
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-07101
Conditions: Hepatitis B - Liver Transplantation Location: Newark, NJ
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-10029
Conditions: Hepatitis B - Liver Transplantation Location: New York, NY
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-15123
Conditions: Hepatitis B - Liver Transplantation Location: Pittsburgh, PA
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-44195
Conditions: Hepatitis B - Liver Transplantation Location: Cleveland, OH
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-60611
Conditions: Hepatitis B - Liver Transplantation Location: Chicago, IL
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-75246
Conditions: Hepatitis B - Liver Transplantation Location: Dallas, TX
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-77030
Conditions: Hepatitis B - Liver Transplantation Location: Houston, TX
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-90033
Conditions: Hepatitis B - Liver Transplantation Location: Los Angeles, CA
- Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients - NCT00722332-94304
Conditions: Hepatitis B - Liver Transplantation Location: Palo Alto, CA
- Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C - NCT00828269-10065
Conditions: Chronic Hepatitis C Location: New York, NY
- FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy - NCT00125762-
Conditions: Cirrhosis - Hepatitis B - Hepatitis C Location: Durham, NC
- FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy - NCT00125762-02215
Conditions: Cirrhosis - Hepatitis B - Hepatitis C Location: Boston, MA
- Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects - NCT00987337-32803
Conditions: Hepatitis - Hepatitis C Location: Orlando, FL
- Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects - NCT00987337-33143
Conditions: Hepatitis - Hepatitis C Location: South Miami, FL
- Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects - NCT00987337-80113
Conditions: Hepatitis - Hepatitis C Location: Englewood, CO
- Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy - NCT00749138-73104
Conditions: Chronic Hepatitis C Location: Oklahoma City, OK
- Genetic Analysis of Liver Cancer - NCT00768001-94305
Conditions: Hepatitis B - Liver Cancer - Hepatitis C Location: Stanford, CA
- Genetics of Hepatitis C Virus Infection - NCT00005657-20892
Conditions: Hepatitis C - Liver Disease Location: Bethesda, MD
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-19104
Conditions: Hepatitis C - Hepatitis C, Chronic Location: Philadelphia, PA
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-44195
Conditions: Hepatitis C - Hepatitis C, Chronic Location: Cleveland, OH
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-48109
Conditions: Hepatitis C - Hepatitis C, Chronic Location: Ann Arbor, MI
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-60208
Conditions: Hepatitis C - Hepatitis C, Chronic Location: Chicago, IL
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-76798
Conditions: Hepatitis C - Hepatitis C, Chronic Location: Dallas, TX
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-80262
Conditions: Hepatitis C - Hepatitis C, Chronic Location: Denver, CO
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-94143
Conditions: Hepatitis C - Hepatitis C, Chronic Location: San Francisco, CA
- Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant - NCT00135694-98195
Conditions: Hepatitis C - Hepatitis C, Chronic Location: Seattle, WA
- Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV - NCT00926146-90028
Conditions: Hepatitis B - Hepatitis C - HIV - HIV Infections Location: Los Angeles, CA
- Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders - NCT00704106-75093
Conditions: Hepatitis B Location: Plano, TX
- Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders - NCT00704106-77072
Conditions: Hepatitis B Location: Houston, TX
- Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders - NCT00704106-95116
Conditions: Hepatitis B Location: San Jose, CA
- Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders - NCT00704106-95128
Conditions: Hepatitis B Location: San Jose, CA
- Hepatitis C Treatment and Atherosclerosis - NCT00659256-20892
Conditions: Chronic Hepatitis C - Atherosclerosis Location: Bethesda, MD
- Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial - NCT00211692-55417
Conditions: Chronic Hepatitis C Location: Minneapolis, MN
- Hepatitis C Virus and the Humoral Immune System - NCT00219999-10021
Conditions: Hepatitis C Virus Location: New York, NY
- High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1 - NCT00735969-20892
Conditions: Chronic Hepatitis C Location: Bethesda, MD
- HIV and Hepatitis Care Coordination in Methadone Treatment - NCT00608192-10003
Conditions: Hepatitis, Viral, Human - HIV Infections Location: New York, NY
- HIV and Hepatitis Care Coordination in Methadone Treatment - NCT00608192-94110
Conditions: Hepatitis, Viral, Human - HIV Infections Location: San Francisco, CA
- Immune Response to Hepatitis C Virus - NCT00006301-20892
Conditions: Hepatitis C Location: Bethesda, MD
- Immune Response to Hepatitis C Virus - NCT00165919-30306
Conditions: Hepatitis C - HIV Infections Location: Atlanta, GA
- Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients - NCT00985426-
Conditions: Chronic Kidney Disease Location: Norfolk, VA
- Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients - NCT00871845-15213
Conditions: Obesity - Insulin Resistance - Metabolic Syndrome - Hepatitis C Location: Pittsburgh, PA
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|